Immunocore Holdings plc (NASDAQ:IMCR) Shares Acquired by Marshall Wace LLP

Marshall Wace LLP lifted its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 14.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 248,654 shares of the company’s stock after purchasing an additional 30,703 shares during the period. Marshall Wace LLP owned approximately 0.50% of Immunocore worth $8,427,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Wellington Management Group LLP lifted its stake in Immunocore by 10.2% during the fourth quarter. Wellington Management Group LLP now owns 4,312,611 shares of the company’s stock valued at $294,638,000 after buying an additional 399,201 shares in the last quarter. Primecap Management Co. CA lifted its position in shares of Immunocore by 3,841.6% in the 2nd quarter. Primecap Management Co. CA now owns 1,951,070 shares of the company’s stock valued at $66,122,000 after acquiring an additional 1,901,570 shares in the last quarter. Bellevue Group AG boosted its stake in Immunocore by 4,817.1% in the 4th quarter. Bellevue Group AG now owns 976,054 shares of the company’s stock worth $66,684,000 after purchasing an additional 956,204 shares during the period. Fiera Capital Corp grew its position in Immunocore by 1.1% during the 2nd quarter. Fiera Capital Corp now owns 875,593 shares of the company’s stock worth $29,674,000 after purchasing an additional 9,181 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in Immunocore by 14.5% during the 2nd quarter. Renaissance Technologies LLC now owns 646,920 shares of the company’s stock valued at $21,924,000 after purchasing an additional 82,120 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on IMCR shares. Barclays decreased their target price on Immunocore from $92.00 to $66.00 and set an “overweight” rating for the company in a research report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Immunocore in a research note on Tuesday, September 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a research report on Monday, September 9th. Needham & Company LLC decreased their price target on shares of Immunocore from $81.00 to $78.00 and set a “buy” rating for the company in a report on Tuesday, September 17th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $89.00 price objective (up previously from $87.00) on shares of Immunocore in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, Immunocore presently has an average rating of “Moderate Buy” and a consensus target price of $80.40.

Immunocore Stock Performance

Shares of IMCR opened at $31.40 on Monday. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -25.74 and a beta of 0.73. The company’s fifty day moving average is $35.94 and its 200-day moving average is $45.16. The company has a quick ratio of 5.15, a current ratio of 5.17 and a debt-to-equity ratio of 1.31. Immunocore Holdings plc has a 12 month low of $29.76 and a 12 month high of $76.98.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.25. The company had revenue of $75.40 million for the quarter, compared to analyst estimates of $74.58 million. Immunocore had a negative return on equity of 14.68% and a negative net margin of 19.16%. The business’s revenue was up 26.2% compared to the same quarter last year. During the same period last year, the company earned ($0.37) earnings per share. Equities analysts expect that Immunocore Holdings plc will post -1.79 EPS for the current fiscal year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.